Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
NCT05907096Phase 2Active, not recruiting
- Sponsor
- argenx
- Start
- Feb 2024
- Primary completion
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in delayed graft function (DGF) comparing ARGX-117 with Placebo (2 arms). Primary endpoint: Estimated Glomerular Filtration Rate at 24 weeks. Started Feb 2024; status: active, not recruiting.
02
Drugs
empasiprubart
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT05907096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907096.